Control of advanced cancer: The road to chronicity

International Journal of Environmental Research and Public Health

Volumn 8, Issue 3, 2011, Pages 683-697

  Lage, Agustin ^a   Crombet, Tania ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Advanced cancer; Biotechnology; Chronic treatment; Small molecules

Indexed keywords

ADVANCED CANCER; ARTICLE; BIOLOGICAL THERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHRONICITY; CLINICAL RESEARCH; EVIDENCE BASED MEDICINE; HUMAN; LONG TERM CARE; NONHUMAN; PUBLIC HEALTH; QUALITY OF LIFE;

EID: 79953273918     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph8030683     Document Type: Article

References (68)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60, 277-300.
2. Ferlay, J.; Parkin, D.M.; Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46, 765-781.
3. Breakaway: The Global Burden of Cancer: Challenges and Opportunities; Economist Intelligence Unit: London, UK, 2009; pp. 1-73.
4. Lage, A.; Pascual, M.R.; Pérez, R. Estudios sobre el pronóstico del cáncer mamario. Análisis de las curvas de mortalidad y recaída en el cáncer de mama. Rev. Cub. Oncol. 1986, 2, 21-29.
5. Balducci, L.; Ershler, W.B. Cancer and ageing: A nexus at several levels. Nat. Rev. Cancer 2005, 5, 655-662.
6. The World Health Report 2008: Primary Health Care Now More Than Ever; World Health Organization: Geneva, Switerland, 2008; pp. 1-119.
7. Ramsey, S.D.; Howlader, N.; Etzioni, R.D.; Donato, B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: Evidence from surveillance, epidemiology and end results-Medicare. J. Clin. Oncol. 2004, 22, 4971-4878.
8. Fernandez Garrote, L.; Graupera Boschmonar, M.; Galan Alvarez, Y.; Lezcano Cicilli, M.; Martin Garcia, A.; Camacho Rodriguez, R. Cancer survival in Cuba. IARC Sci. Publ. 1998, 145, 51-59.
9. Graupera Boschmonar, M.C.; Jiménez Chaviano, P.J.; Martín García, A.A.; Galán Alvarez, Y.H.; Fernández Garrote, L.M.; Sankaranarayanan, R. Trends in survival rates of cancer in Cuba. Eur. J. Epidemiol. 1999, 15, 521-528.
10. Alonso, E.D.; Jo, A.H.; Galán, Y. The burden of disease from cancer in Cuba, 1990-2002. Rev. Panam. Salud. Publica. 2009, 26, 412-418.
11. Brenner, H. Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet 2002, 360, 1131-1135.
12. Giordano, S.H.; Buzdar, A.U.; Smith, T.L.; Kau, S.W.; Yang, Y.; Hortobagyi, G.N. Is breast cancer survival improving? Cancer 2004, 100, 44-52.
13. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329, 977-986.
14. Marin, D. Current status of imatinib as frontline therapy for chronic myeloid leukemia. Semin. Hematol. 2010, 47, 312-318.
15. Cirocchi, R.; Farinella, E.; La Mura, F.; Cavaliere, D.; Avenia, N.; Verdecchia, G.M.; Giustozzi, G.; Noya, G.; Sciannameo, F. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: A systematic review. Tumori 2010, 96, 392-399.
16. Sulkes, A. Novel multitargeted anticancer oral therapies: Sunitinib and sorafenib as a paradigm. Isr. Med. Assoc. J. 2010, 12, 628-632.
17. Caponi, S.; Vasile, E.; Ginocchi, L.; Tibaldi, C.; Borghi, F.; D'Incecco, A.; Lucchesi, M.; Caparello, C.; Andreuccetti, M.; Falcone, A. Second-line treatment for non-small-cell lung cancer: One size does not fit all. Clin. Lung. Cancer 2010, 11, 320-327.
18. Laack, E.; Sauter, G.; Bokemeyer, C. Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer. Lung Cancer 2010, 69, 259-264.
19. Weiner, L.M.; Surana, R.; Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10, 317-327.
20. Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; Xu, Y.; Frohlich, M.W.; Schellhammer, P.F. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363, 411-422.
21. 2008 Report: Medicines in Development. Biotechnology; Pharmaceutical Research and Manufacturers of America: Washington, DC, USA, 2004; pp. 1-60.
22. Monoclonal Antibodies: 2009 Update; Datamonitor: London, UK, 2009; pp. 1-243; Product code DMHC2579.
23. Mannocci, A.; De Feo, E.; de Waure, C.; Specchia, M.L.; Gualano, M.R.; Barone, C.; Ricciardi, W.; La Torre, G. Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: A systematic review of published studies. Tumori 2010, 96, 385-391.
24. Kozloff, M.F.; Berlin, J.; Flynn, P.J.; Kabbinavar, F.; Ashby, M.; Dong, W.; Sing, A.P.; Grothey, A. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: Results from the BRiTE observational cohort study. Oncology 2010, 78, 329-339.
25. Moschella, F.; Proietti, E.; Capone, I.; Belardelli, F. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients. Ann. N Y Acad. Sci. 2010, 1194, 169-178.
26. Richards, L. Chemotherapy. Conventional chemotherapy boosts the effect of cancer vaccines. Nat. Rev. Clin. Oncol. 2010, 7, 297.
27. Emens, L.A. Chemoimmunotherapy. Cancer J. 2010, 16, 295-303.
28. Chen, C.A.; Ho, C.M.; Chang, M.C.; Sun, W.Z.; Chen, Y.L.; Chiang, Y.C.; Syu, M.H.; Hsieh, C.Y.; Cheng, W.F. Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis. Mol. Ther. 2010, 18, 1233-1243.
29. Ghiringhelli, F.; Menard, C.; Puig, P.E.; Ladoire, S.; Roux, S.; Martin, F.; Solary, E.; Le Cesne, A.; Zitvogel, L.; Chauffert, B. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56, 641-648.
30. Hoos, A.; Parmiani, G.; Hege, K.; Sznol, M.; Loibner, H.; Eggermont, A.; Urba, W.; Blumenstein, B.; Sacks, N.; Keilholz, U.; Nichol, G.; Cancer Vaccine Clinical Trial Working Group. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 2007, 30, 1-15.
31. Finke, L.H.; Wentworth, K.; Blumenstein, B.; Rudolph, N.S.; Levitsky, H.; Hoos, A. Lessons from randomized phase III studies with active cancer immunotherapies-outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007, 25 Suppl 2, B97-B109.
32. Wolchok, J.D.; Hoos, A.; O'Day, S. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 2009, 15, 7412-7420.
33. Hoos, A.; Eggermont, A.M.; Janetzki, S.; Hodi, F.S.; Ibrahim, R.; Anderson, A.; Humphrey, R.; Blumenstein, B.; Old, L.; Wolchok, J. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 2010, 102, 1388-1397.
34. Lee, J.J.; Feng, L. Randomized phase II designs in cancer clinical trials: Current status and future directions. J. Clin. Oncol. 2005, 23, 4450-4457.
35. Provencio, M.; Camps, C.; Alberola, V.; Massutti, B.; Viñolas, N.; Isla, D.; Dómine, M.; Millán, I.; Cobo, M.; Rosell, R. Lung cancer and treatment in elderly patients: The Achilles Study. Lung Cancer 2009, 66, 103-106.
36. Elting, L.S.; Cooksley, C.; Bekele, B.N.; Frumovitz, M.; Avritscher, E.B.; Sun, C.; Bodurka, D.C. Generalizability of cancer clinical trial results: Prognostic differences between participants and nonparticipants. Cancer 2006, 106, 2452-2458.
37. Weiss, N.S. Generalizability of cancer clinical trial results. Cancer 2007, 109, 341; author reply 342.
38. Lage, A. Connecting immunology research to public health: Cuban biotechnology. Nat. Immunol. 2008, 9, 109-112.
39. Talavera, A.; Friemann, R.; Gómez-Puerta, S.; Martinez-Fleites, C.; Garrido, G.; Rabasa, A.; López-Requena, A.; Pupo, A.; Johansen, R.F.; Sánchez, O.; Krengel, U.; Moreno, E. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009, 69, 5851-5859.
40. Rodríguez, M.O.; Rivero, T.C.; del Castillo Bahi, R.; Muchuli, C.R.; Bilbao, M.A.; Vinageras, E.N.; Alert, J.; Galainena, J.J.; Rodríguez, E.; Gracias, E.; Mulén, B.; Wilkinson, B.; de Armas, E.L.; Pérez, K.; Pineda, I.; Frómeta, M.; Leonard, I.; Mullens, V.; Viada, C.; Luaces, P.; Torres, O.; Iznaga, N.; Crombet, T. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol. Ther. 2010, 9, 343-349.
41. Ramakrishnan, M. S; Eswaraiah, A.; Crombet, T.; Piedra, P.; Saurez, G.; Iyer, H.; Arvind, A.S. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009, 1, 41-48.
42. Rodríguez, P.C.; Rodríguez, G.; González, G.; Lage, A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. 2010, 12, 17-23.
43. Neninger Vinageras, E.; de la Torre, A.; Osorio Rodríguez, M.; Catalá Ferrer, M.; Bravo, I.; Mendoza del Pino, M.; Abreu Abreu, D.; Acosta Brooks, S.; Rives, R.; del Castillo Carrillo, C.; González Dueñas, M.; Viada, C.; García Verdecia, B.; Crombet Ramos, T.; González Marinello, G.; Lage Dávila, A. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J. Clin. Oncol. 2008, 26, 1452-1458.
44. Roque-Navarro, L.; Chakrabandhu, K.; de León, J.; Rodríguez, S.; Toledo, C.; Carr, A.; de Acosta, C.M.; Hueber, A.O.; Pérez, R. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol. Cancer Ther. 2008, 7, 2033-2041.
45. Montero, E.; Falcon, L.; Morera, Y.; Delgado, J.; Amador, J.F.; Perez, R. CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease. Autoimmunity 1999, 29, 155-156.
46. Mulens, V.; de la Torre, A.; Marinello, P.; Rodríguez, R.; Cardoso, J.; Díaz, R.; O'Farrill, M.; Macias, A.; Viada, C.; Saurez, G.; Carr, A.; Crombet, T.; Mazorra, Z.; Perez, R.; Fernandez, L.E. Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients. Hum. Vaccin. 2010, 6, 736-744.
47. Hernández, A.M.; Toledo, D.; Martínez, D.; Griñán, T.; Brito, V.; Macías, A.; Alfonso, S.; Rondón, T.; Suárez, E.; Vázquez, A.M.; Pérez, R. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J. Immunol. 2008, 181, 6625-6634.
48. Basavaraj, C.; Sierra, P.; Shivu, J.; Melarkode, R.; Montero, E.; Nair, P. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. Cancer Biol. Ther. 2010, 10, 673-681.
49. Ramos, T.C.; Figueredo, J.; Catala, M.; González, S.; Selva, J.C.; Cruz, T.M.; Toledo, C.; Silva, S.; Pestano, Y.; Ramos, M.; Leonard, I.; Torres, O.; Marinello, P.; Pérez, R.; Lage, A. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. Cancer Biol. Ther. 2006, 5, 375-379.
50. Casacó, A.; López, G.; García, I.; Rodríguez, J.A.; Fernández, R.; Figueredo, J.; Torres, L.; Perera, A.; Batista, J.; Leyva, R.; Peña, Y.; Amador, Z.; González, A.; Estupiñan, B.; Coca, M.; Hernández, A.; Puig, M.; Iglesias, M.; Hernández, A.; Ramos, M.; Rodríquez, L.; Suarez, N. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol. Ther. 2008, 7, 333-339.
51. Allan, D.G. Nimotuzumab: Evidence of clinical benefit without rash. Oncologist 2005, 10, 760-761.
52. Boland, W.K.; Bebb, G. Nimotuzumab: A novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin. Biol. Ther. 2009, 9, 1199-1206.
53. Neninger, E.; Verdecia, B.G.; Crombet, T.; Viada, C.; Pereda, S.; Leonard, I.; Mazorra, Z.; Fleites, G.; González, M.; Wilkinson, B.; González, G.; Lage, A. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J. Immunother. 2009, 32, 92-99.
54. Gonzalez,. G.; Crombet, T.; Lage, A. Chronic Vaccination with a Therapeutic EGF-Based Cancer Vaccine: A Review of Patients Receiving Long Lasting Treatment. Curr. Cancer Drug Targets 2010, 11, 103-110.
55. Shepperd, S.; Lewin, S.; Straus, S.; Clarke, M.; Eccles, M.P.; Fitzpatrick, R.; Wong, G.; Sheikh, A. Can we systematically review studies that evaluate complex interventions? PLoS Med. 2009, 6, e1000086.
56. Craig, P.; Dieppe, P.; Macintyre, S.; Michie, S.; Nazareth, I.; Petticrew, M. Medical Research Council Guidance. Developing and evaluating complex interventions: The new Medical Research Council guidance. BMJ 2008, 337, a1655.
57. Murray, E.; Treweek, S.; Pope, C.; MacFarlane, A.; Ballini, L.; Dowrick, C.; Finch, T.; Kennedy, A.; Mair, F.; O'Donnell, C.; Ong, B.N.; Rapley, T.; Rogers, A.; May, C. Normalisation process theory: A framework for developing, evaluating and implementing complex interventions. BMC Med. 2010, 8, 63.
58. Rowland, K.; Schumann, S.A. Palliative care: Earlier is better. J. Fam. Pract. 2010, 59, 695-698.
59. Malik, N.N. Controlling the cost of innovative cancer therapeutics. Nat. Rev. Clin. Oncol. 2009, 4, 550-552.
60. Scolnik, P.A. mAbs: a business perspective. MAbs 2009, 1, 179-184.
61. Ferris, R.L.; Jaffee, E.M.; Ferrone, S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: Clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 2010, 28, 4390-4399.
62. Peggs, K.S.; Quezada, S.A. Ipilimumab: Attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. Expert Rev. Anticancer Ther. 2010, 10, 1697-1701.
63. Jacobs, J.F.; Punt, C.J.; Lesterhuis, W.J.; Sutmuller, R.P.; Brouwer, H.M.; Scharenborg, N.M.; Klasen, I.S.; Hilbrands, L.B.; Figdor, C.G.; de Vries, I.J.; Adema, G.J. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: A phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 2010, 16, 5067-5078.
64. Hayflick, L. The future of ageing. Nature 2000, 408, 267-269.
65. Aw, D.; Silva, A.B.; Palmer, D.B. Immunosenescence: Emerging challenges for an ageing population. Immunology 2007, 120, 435-446.
66. Shrikant, P.; Mescher, M.F. Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J. Immunol. 2002, 169, 1753-1759.
67. de Visser, K.E.; Eichten, A.; Coussens, L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006, 6, 24-37.
68. Coleman, M.P.; Gatta, G.; Verdecchia, A.; Estève, J.; Sant, M.; Storm, H.; Allemani, C.; Ciccolallo, L.; Santaquilani, M.; Berrino, F.; EUROCARE Working Group. EUROCARE-3 summary: Cancer survival in Europe at the end of the 20th century. Ann. Oncol. 2003, 14 (Suppl 5), v128-v149.